Intrinsic Value Partners LLC Takes $206,000 Position in Johnson & Johnson (NYSE:JNJ)

Intrinsic Value Partners LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 1,273 shares of the company’s stock, valued at approximately $206,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $765,000. Empowered Funds LLC increased its holdings in Johnson & Johnson by 46.7% during the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after purchasing an additional 32,244 shares during the last quarter. Equity Investment Corp raised its position in shares of Johnson & Johnson by 6.0% in the 1st quarter. Equity Investment Corp now owns 88,922 shares of the company’s stock valued at $14,067,000 after purchasing an additional 4,998 shares in the last quarter. Zevenbergen Capital Investments LLC grew its position in shares of Johnson & Johnson by 3.5% during the first quarter. Zevenbergen Capital Investments LLC now owns 14,894 shares of the company’s stock worth $2,356,000 after buying an additional 500 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. increased its stake in shares of Johnson & Johnson by 16.7% in the first quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 21,000 shares of the company’s stock worth $3,322,000 after buying an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $155.05 on Tuesday. The firm has a market capitalization of $373.30 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The stock’s fifty day moving average is $162.61 and its 200-day moving average is $155.91. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the business posted $2.66 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Citigroup upped their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.